Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Peruvian
100%
Mestizo
100%
Pharmacogenetics
100%
N-acetyltransferase 2 (NAT2)
100%
Tuberculosis Biomarkers
100%
Drug-induced Liver Injury
45%
Cytochrome P450 2E1 (CYP2E1)
36%
Mestizo Population
36%
Genotype
27%
Tuberculosis
18%
Peru
18%
Single nucleotide Polymorphism
18%
Native Population
18%
C1-C2
18%
Lima
9%
Latin America (LATAM)
9%
Limited Information
9%
Prevalence Ratio
9%
Liver
9%
Sectional Analysis
9%
Tuberculosis Treatment
9%
Molecular Diagnostics
9%
Linkage Disequilibrium
9%
Adverse Drug Reaction
9%
First-line Anti-tuberculosis Drugs
9%
Rs1801280
9%
Decreased Risk
9%
Secondary Study
9%
Anti-tuberculosis Drugs
9%
Injury Risk
9%
CYP2E
9%
Metabolizer
9%
Genetic Data
9%
Molecular Bioinformatics
9%
Bioinformatics Analysis
9%
New Therapeutic Strategies
9%
Genetic Risk
9%
Control Efficacy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacogenetics
100%
Acyltransferase
100%
Biological Marker
100%
Toxic Hepatitis
45%
CYP2E1
36%
Isoniazid
27%
Prevalence
18%
Tuberculostatic Agent
18%
Cross Sectional Study
9%
Adverse Drug Reaction
9%
Genetic Risk
9%
Neuroscience
N-Acetyltransferase
100%
Cytochrome P450 2E1
36%
Isoniazid
27%
Haplotype
27%
Single-Nucleotide Polymorphism
18%
Linkage Disequilibrium
9%
Risk Factor
9%
Immunology and Microbiology
Biochemistry, Genetics and Molecular Biology